Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win ...
STAT

China’s strict new supply chain regulations could create massive problems for Western biopharma companies

China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
STAT

Hair-raising trial results, and Servier’s M&A wishlist

Why are investors excited about hair loss drugs? Will AI make clinical trials run more smoothly? And more in "The Readout ...

Biostatistics for Non-Statisticians Practical Guide Webinar: Designed Specifically for Professionals with Little or No Statistical Background (LIVE & ON-DEMAND May 26th - May ...

The main market opportunities lie in offering practical statistical training tailored for professionals without a statistical background to enhance collaboration with data teams. Emphasizing ...

Strengthen Readiness for a Potential SAS-to-R Shift in Data Analytics, Upcoming Webinar Hosted by Xtalks

For decades, SAS has been regarded as the industry standard for statistical programming and regulatory submissions in ...

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...